Metabolic studies with probucol in hypercholesterolaemia

Area of Science:

• Cardiology
• Pharmacology
• Gastroenterology

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular disease.
• Dietary interventions are the first line of treatment for hypercholesterolemia.
• Pharmacological agents are often required to achieve target lipid levels.

Purpose of the Study:

• To evaluate the effects of Probucol on lipid profiles in hypercholesterolemic patients.
• To investigate the impact of Probucol on bile acid metabolism and cholesterol saturation.
• To assess the influence of Probucol on platelet activation in vivo.

Main Methods:

• 16 hypercholesterolemic patients stabilized on diet received 1 g/day Probucol for 6 months.
• Plasma lipid levels (total cholesterol, LDL, HDL, triglycerides) were monitored.
• Faecal steroid excretion, gall bladder bile composition, and platelet activation markers were assessed in subsets of patients.

Main Results:

• Probucol reduced total cholesterol by 16%, LDL cholesterol by 14%, and HDL cholesterol by 41%.
• The total cholesterol to HDL cholesterol ratio increased by 40%; triglycerides showed a slight upward trend.
• Probucol increased faecal steroid excretion, enhanced cholesterol saturation in bile, and reduced platelet activation.

Conclusions:

• Probucol effectively lowers LDL cholesterol but significantly reduces HDL cholesterol.
• The drug impacts bile acid metabolism and may increase the risk of gallstone formation.
• Probucol demonstrates potential antiplatelet effects, warranting further investigation.